FILTER CONTENT

Filters
Company Names

Research

  • 7investing logo next to the Avita Medical logo.
    By Published On: February 17, 2025

    AVITA Medical: 2025 Will Be an “Inflection Point Year”

    AVITA Medical is continuing to show signs of progress. Its recently-reported fourth quarter [...]

  • By Published On: September 19, 2024

    September 2024 Conviction Rating Review

  • By Published On: August 26, 2024

    Here are 3 Key Risks at TransMedics. But the Stock is Still a Buy.

  • By Published On: August 19, 2024

    7investing Exclusive: Sell These 8 Stocks

  • By Published On: August 19, 2024

    Sell Seres Therapeutics

  • 7investing logo next to the Taiwan Semiconductor logo.
    By Published On: June 28, 2024

    Taiwan Semi: One of AI’s Biggest Winners Not Named “NVIDIA”

  • By Published On: June 11, 2024

    Seres is Blowing Up its Business. Here’s What Investors Need to Know.

  • 7investing logo next to the Taiwan Semiconductor logo.
    By Published On: February 6, 2024

    Taiwan Semiconductor: Still a Buy, But Risk Profile is Rising

  • By Published On: December 18, 2023

    7investing’s 2023 Year in Review: An Updated Look at All of Our Stock Picks

  • By Published On: October 19, 2023

    The Seres Dilemma: VOWST is Approved, But the Stock is Falling

  • 7investing logo next to MongoDB logo.
    By Published On: September 7, 2023

    MongoDB is Boldly Disrupting the Database Market

  • 7investing logo next to the Cloudflare logo.
    By Published On: August 3, 2023

    Cloudflare’s Q2 2023 Surprises Wall Street

  • 7investing logo next to MongoDB logo.
    By Published On: June 13, 2023

    MongoDB Starts Fiscal 2024 With A Bang

  • 7investing logo next to the Cloudflare logo.
    By Published On: May 1, 2023

    Cloudflare Downgrades Fiscal 2023 Guidance: Moving to Hold

  • 7investing logo next to the Taiwan Semiconductor logo.
    By Published On: March 23, 2023

    GPT-4 is About to Become a Gold Mine for Taiwan Semi

  • By Published On: February 10, 2023

    Affirm Navigates a Turbulent Macro; Shares Still a “Buy”